Microsoft word - master_references.doc

References Acute Lymphocytic Leukemia 7 Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000) Martin Schrappe, MD, Martin Zimmermann, PhD, Anja Möricke, MD, Georg Mann, MD, Maria Grazia Valsecchi, PhD, Claus R Bartram, MD, Andrea Biondi, MD, Renate Panzer-Grümayer, MD, André Schrauder, MD, Franco Locatelli, MD, Alfred Reiter, MD, Giuseppe Basso, MD, Felix Niggli, MD, Maurizio Aricò, MD and Valentino Conter, MD 10 High-Dose Methotrexate Seems to Benefit Only to Standard-Risk BCP-ALL Patients with Good Early Response to Chemotherapy: Final Analysis of the FRALLE93B Study Thierry Leblanc, MD, Judith Landman-Parker, MD, Marie-Françoise Auclerc, MD, Krystell Desseaux, Christiane Vermylen, MD, Claudine Schmitt, MD, Virginie Gandemer, MD, Odile Lejars, MD, Jean-Pierre Vannier, MD, François Demeocq, MD, Christian Berthou, MD, Gérard Couillault, MD, Brigitte Pautard, MD, Claire Berger, MD, Lionel De Lumley, MD, Marianne Debré, MD, Gérard Michel, MD, Yves Perel, MD, Guy Leverger, MD and Andre Baruchel, MD 11 Improved Outcome with Pulses of Vincristine and Steroids in Continuation Therapy of Children with Average Risk Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL): Final Report of the EORTC Randomized Phase III Trial 58951 Barbara De Moerloose, Stefan Suciu, Yves Bertrand, Francoise Mazingue, Alain Robert, Anne Uyttebroeck, Karima Yacouben, Alina Ferster, Geneviève Margueritte, Patrick Lutz, Martine Munzer, Nicolas Sirvent, Lucilia Norton, Patrick Boutard, Dominique Plantaz, Frédéric Millot, Pierre Philippet, Liliana Baila, Yves Benoit and Jacques Otten* 303 Prognostic Significance of Central Nervous System (CNS) Status of Children with Acute Lymphoblastic Leukemia (ALL) Treated without Cranial Irradiation: Results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group Study 58951 Nicolas Sirvent, Stefan Suciu, Yves Benoit, Yves Bertrand, Brigitte Nelken, Alain Robert, Anne Uyttebroeck, Patrick Lutz, MD, Alina Ferster, MD, PhD, Karima Yacouben, Lucilia Norton, Geneviève Margueritte, Martine Munzer, Dominique Plantaz, Frédéric Millot, Patrick Boutard, Pierre Philippet, Claire Hoyoux, Liliana Baila and Jacques Otten 305 Line Treatment of Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Final Results of the GIMEMA LAL1205 Study Robert Foà, Antonella Vitale, Anna Guarini, Maria Sefania De Propris, Loredana Elia, Giuseppe Cimino, Mario Luppi, Carlo Castagnola, Simona Sica, Rosa Nieddu, Maria-Novella Piersantelli, Felicetto Ferrara, Francesco Nobile, Renato Fanin, Francesco Fabbiano, Marco Vignetti, Paola Fazi, Simona Soverini, Franco Mandelli, Giovanni Martinelli, Giovanna Meloni and Michele Baccarani 908 Improved Outcome for Children and Young Adults with T-Cell Acute Lymphoblastic Leukaemia (ALL): Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003 Ajay Vora, Rachel Wade, Christopher D Mitchell, Nicholas Goulden and Sue Richards 909 Efficacy and Toxicity of Pegylated Asparaginase in the Treatment of Children and Young Adults with Acute Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003 Ajay Vora, Rachel Wade, Christopher Mitchell, Nicholas Goulden and Sue Richards 917 Survival after Relapse in Higher Risk Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Is Independent of Prior Treatment Intensity: A Report from the Children’s Oncology Group (COG) David Robert Freyer, DO, Nita L. Seibel, MD, Mei K La, MS, Meenakshi Devidas, PhD, William L. Carroll, MD, Stephen P. Hunger, MD and Paul S. Gaynon, MD 1929 Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukemia (ALL) Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Jorge Cortes, MD, Stefan Faderl, MD, William G. Wierda, MD, PhD, Farhad Ravandi, MBBS, Maria Alma Rodriguez, MD, Luis Fayad, MD and Susan O'Brien, MD 1930 Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) after Frontline Therapy with Hyper-CVAD Regimens Deborah A. Thomas, MD, Susan O'Brien, MD, Michael Rytting, MD, Stefan Faderl, MD, Jorge Cortes, MD, William G. Wierda, MD, PhD, Farhad Ravandi, MBBS and Hagop M Kantarjian 1931 Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) Deborah A. Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, William G. Wierda, MD, Ph.D, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Jorge Cortes, MD, Charles A. Koller, MD, Gautam Borthakur, MBBS, Zeev Estrov, Marina Konopleva, MD, PhD, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, MD and Susan O'Brien, MD 2919 Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB) Elias Jabbour, Susan O'Brien, Deborah A. Thomas, Stefan Faderl, MD, Charles Asa Koller, MD, Samuel Dara, Coordinator, Clinical, Studies, Rebecca Garris, Data, Analyst, Jorge Cortes, MD, Hagop M Kantarjian and Farhad Ravandi 2931 Outcome after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen for Adults with De Novo or Minimally Treated Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Deborah A. Thomas, MD, Hagop M Kantarjian, Jorge Cortes, MD, Farhad Ravandi, MBBS, Stefan Faderl, MD, Dan Jones, MD, PhD, Laurie A. Letvak, MD, Partow Kebriaei, MD, Richard E Champlin, MD and Susan O'Brien, MD Acute Myelogenous Leukemia 133 Addition of Cladribine to the Standard Daunorubicine - Cytarabine (DA 3+7) Remission Induction Protocol (DAC) Contrary to Adjunct of Fludarabine (DAF) Improves the Overall Survival in Untreated Adults with Acute Myeloid Leukemia Aged up to 60 Y: A Multicenter, Randomized, Phase III PALG AML 1/2004 DAF/DAC/DA Study in 673 Patients Jerzy Holowiecki, Sebastian Grosicki, Slawomira Kyrcz-Krzemien, Kazimierz Kuliczkowski, Aleksander B. Skotnicki, Andrzej Hellmann, MD, PhD, Tadeusz Robak, MD, PhD, Kazimierz Sulek, Anna Dmoszynska, Janusz Kloczko, Wieslaw Wiktor Jedrzejczak, Barbara Zdziarska, Krzysztof Warzocha, Krystyna Zawilska, Marek Kielbinski, Beata Piatkowska-Jakubas, Agnieszka Wierzbowska, Olga Haus, Beata Stella-Holowiecka, Malgorzata Krawczyk-Kulis, Malgorzata Wach and Anna Ejduk 134 High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups) Roelof Willemze, MD, PhD, Stefan Suciu, Franco Mandelli, Boris Labar, MD, PhD, Jean-Pierre Marie, Martin Mistrik, MD, PhD, Vincenzo Liso, Francesco Fabbiano, Francesco Nobile, Marco Sborgia, Bruno Rotoli, Dominik L.D. Selleslag, MD, Francois Lefrere Sr., MD, Antonio Peta, Massimo F Martelli, Giuseppe Leone, Nicola Cantore, Meral Beksac, Zwi Berneman, Xavier Thomas, Michele Mario Greco, Dominique Bron, Georges Fillet, Jose E. Guimaraes, MD, PhD, Petra Muus, Paola Fazi, Liliana Baila, Marco Vignetti, Sergio Amadori, Theo de Witte on behalf of the European Group for Blood and Marrow Transplantation and Giovanna Meloni 761 Improved Outcome by Addition of Lomustine (CCNU) to Idarubicin and Cytarabine in Elderly Patients with De Novo Acute Myeloid Leukemia. A Report from the GOELAMS Group Arnaud Pigneux, MD, PhD, Francis Witz, Mathieu Sauvezie, Marie-Christine Bene, MD, PhD, Isabelle Luquet, MD, PhD, Mathilde hunault-Berger, MD, PhD, Christian Recher, MD, Ph.D, Norbert Vey, MD, Bruno Lioure, MD, Chantal Himberlin, MD, Martine Escoffre-Barbe, MD, Christian Berthou, Severine Lissandre, Nathalie Fegueux, MD, Jean-Yves Cahn, MD, PhD, Eric Jourdan, MD, PhD, Didier Bouscary, MD, PhD, Francois Dreyfus, Josy M. Reiffers, Noel Milpied, MD, Jean-Luc Harousseau, MD and Norbert Ifrah, MD 762 Phase II-III Study of Gemtuzumab Ozogamicin Monotherapy versus Best Supportive Care in Older Patients with Newly Diagnosed AML Unfit for Intensive Chemotherapy: First Results of the EORTC-GIMEMA AML-19 Trial Sergio Amadori, Stefan Suciu, Dominik Selleslag, Giuliana Alimena, Liliana Baila, Vittorio Rizzoli, Giuseppe Rossi, Gianluca Gaidano, Domenico Magro, Giuseppe Torelli, Petra Muus, Adriano Venditti, Emma Cacciola, Francesco Lauria, Filip Beeldens, Marco Vignetti and Theo de Witte 940 Survival after Complete Response to Treatment with Laromustine (CLORETAZINE®) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML) Susan O'Brien, MD, Gary Schiller, Robert Kenneth Stuart, MD, Diana Hudak and Francis Giles, MD 964 Results of a Randomized Phase 2 Study of Clofarabine Plus Cytarabine (CA) Vs Clofarabine Plus Idarubicin (CI) Vs Clofarabine, Idarubicin, Plus Cytarabine (CIA) as Salvage Therapy in Acute Myeloid Leukemia (AML) Stefan Faderl, Gautam Borthakur, Farhad Ravandi, Xuelin Huang, Miloslav Beran, Alessandra Ferrajoli, Charles A. Koller, Deborah A. Thomas, Srdan Verstovsek, Monica Kwari and Hagop M. Kantarjian 1944 Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease Geoffrey L. Uy, MD, Michael P. Rettig, PhD, Kyle M. McFarland, Lindsay M. Hladnik, PharmD, Shashikant Kulkarni, PhD, Camille N. Abboud, MD, Amanda F. Cashen, MD, Keith Stockerl-Goldstein, MD, Ravi Vij, MBBS, Peter Westervelt, MD, PhD and John F. DiPersio, MD, PhD 1951 Phase 2 Study of Voreloxin (Formerly Known as SNS-595) as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Preliminary Safety and Clinical Responses (The REVEAL-1 Study) Michael Maris, MD, Larry D. Cripe, MD, Robert K Stuart, MD, Farhad Ravandi, MBBS, Glenn C Michelson, MD, Rachel E. Hawtin, PhD, Lyra E Ericson and Craig J. Berman, MD 1952 The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG) Jacob M. Rowe, MD, Xiaopan Yao, Ph.D, Peter A. Cassileth, MD, Frederick R. Appelbaum, MD, Peter H. Wiernik, MD, Charles Schiffer, MD, Mark R. Litzow, MD, Selina Luger, MD, John M. Bennett, MD, Hillard M Lazarus, MD and Martin S Tallman 2960 A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial Robert Hills, MA, MSc, DPhil, Susan O'Brien, MD, Verena Karsten, PhD, Alan K. Burnett, MD, FRCP and Francis Giles, MD 2962 Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 “Pick a Winner” Comparison Alan K. Burnett, MD, FRCP, Robert Hills, MA, MSc, DPhil, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, DPhil, Andres E. Virchis, FRCP, FRCPath and Nigel H. Russell, MD 2966 Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraC-Application Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival Cornelia Becker, Rainer Krahl, Antje Schulze, Georg Maschmeyer, Christian Junghanß, Astrid Franke, Norma Peter, Mathias Haenel, Ulrich Wedding, Hans-Heinrich Wolf, Detlev Haehling, Johannes Meran, Gottfried Doelken, Dietrich Kaempfe, Erika Kettner, Norbert Grobe, Axel Florschuetz, Ute Kreibich, Veronika Schirmer, Thomas Ittel, Mathias Schulze, Renate Huhn, Ernst Zschuppe, Bernd Opitz, Michael Assmann, Dirk Hasenclever, Wolfram Poenisch, Werner Helbig and Dietger W. Niederwieser, MD Chronic Lymphocytic Leukemia 43 Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy Neil E. Kay, Wenting Wu, John C. Byrd, MD, Brian Kabat, Diane F. Jelinek, PhD, Clive S. Zent, MD, Timothy Call, Thomas Lin, MD, PhD and Tait Shanafelt 44 A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) Christine Chen, MD, Harminder Paul, Wei Xu, PhD, Vishal Kukreti, Suzanne Trudel, Ellen Wei, Zhi Hua Li, Joseph Brandwein, Mariela Pantoja and Chungyee Leung-Hagensteijn 45 Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Alessandra Ferrajoli, Susan O'Brien, William Wierda, Stefan Faderl, Steven Kornblau, Kimberly Yerrow, Zeev Estrov, Hagop Kantarjian and Michael Keating 46 Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities Thomas S. Lin, MD, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Beth Fischer, BSN, RN, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD, Joseph M. Flynn, DO, MPH, Mollie E. Moran, MSN, CNP, Sarah Mitchell, Amy J. Johnson, PhD, Mitch A. Phelps, PhD, Michael R. Grever, MD and John C. Byrd, MD 325 Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL) Michael Hallek, MD, Guenter Fingerle-Rowson, MD, PhD, Anna- Maria Fink, MD, Raymonde Busch, Jiri Mayer, MD, Manfred Hensel, MD, Georg Hopfinger, MD, Georg Hess, MD, Ulrich von Gruenhagen, MD, Manuela A. Bergmann, MD, John Catalano, MD, Pier Luigi Zinzani, MD, Federico Caligaris Cappio, MD, John Francis Seymour, MBBS, Alain Berrebi, MD, Ulrich Jaeger, MD, Bruno Cazin, MD, Marek Trneny, MD, PhD, Anne Westermann, Clemens-Martin Wendtner, MD, Barbara F. Eichhorst, MD, Peter Staib, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Stephan Stilgenbauer, MD, Myriam Mendila, MD, Michael Kneba, MD, PhD, Hartmut Döhner, MD and Kirsten Fischer, MD 327 Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab Vs. Pentostatin, Cyclophosphamide, and Rituximab in B-Cell Chronic Lymphocytic Leukemia Craig Reynolds, MD, Nicholas Di Bella, MD, Roger M. Lyons, MD, William J Hyman, MD, Gary L. Lee, MD, Donald A Richards, MD, PhD, Gerald J. Robbins, MD, Mark Vellek, MD, Kristi A Boehm, MS, Feng Zhan, PhD and Lina Asmar, PhD 328 Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial Anders Osterborg, MD, PhD, Thomas J. Kipps, MD, PhD, Jiri Mayer, MD, Stephan Stilgenbauer, Prof., Dr., med, Catherine D Williams, MBBS, MRCP, FRCPath, Andrzej Hellmen, MD, PhD, Tadeusz Robak, MD, PhD, Richard R Furman, MD, Peter Hillmen, MBChB, PhD, Marek Trneny, MD, PhD, Martin J.S. Dyer, MA, DPhil, FRCP, Swaminathan Padmanabhan, MD, MBBS, Tomas Kozak, MD, PhD, Geoffrey Chan, MD, Randy L Davis, DrPH, Nedjad Losic, MSc, Charlotte A. Russell, MD, DMSC, Magdalena Piotrowska, MD, Joris Wilms, MSc., Pharm and William G. Wierda, MD, PhD 1053 The Performance of Computed Tomography (CT) Scans or Ultrasound Has No Clinical Relevance in Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Metaanalysis from Three Phase III Studies of the German CLL Study Group (GCLLSG) Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Anna- Maria Fink, MD, Thomas Elter, MD, Clemens M Wendtner, MD, Raymonde Busch, Dipl., math., Michael Hallek and German CLL Study Group 1054 High CD79b Expression Predicts a Poor Outcome in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Giovanni Del Poeta, Maria Ilaria Del Principe, Antonella Zucchetto, Francesco Buccisano, Cristina Simotti, Luca Maurillo, Laura Giannì, Pietro Bulian, Adriano Venditti, Angela Coletta, Pasquale Niscola, Paolo de Fabritiis, Valter Gattei and Sergio Amadori 1057 Predictors of Clinical Outcome to Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath for Relapsed/Refractory CLL – A Study of the Eastern Cooperative Oncology Group, E2903 Neil E. Kay, MD, Haesook T Kim, Ph.D., Sanford Kempin, MD, Charla Secreto, Traci Knox, Renee Tschumper, Diane F Jelinek, Stephanie Smoley, Daniel VanDyke, Joel Saltzman, MD, Steven T. Rosen, MD, Brad Kahl, MD and Martin S. Tallman, MD 1062 Biological and Clinical Relevance of Surrogate Markers of IgVH Mutational Status in B-Cell Chronic Lymphocytic Leukemia Fortunato Morabito, MD, Marta Lionetti, PhD, Giovanna Cutrona, PhD, Katia Todoerti, PhD, Serena Matis, PhD, Massimo Gentile, PhD, Mauro Spriano, PhD, Vincenzo Callea, MD, Gianluca Festini, PhD, Stefano Molica, MD, Giorgio Lambertenghi Deliliers, MD, Manlio Ferrarini, MD and Antonino Neri, MD 2089 Biologic and Clinical Markers for Outcome after Fludarabine (F) or F Plus Cyclophosphamide (FC) - Comprehensive Analysis of the CLL4 Trial of the GCLLSG Stephan Stilgenbauer, Barbara F. Eichhorst, Raymonde Busch, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Valentin Goede, Clemens M Wendtner, Peter Lichter, Berthold Emmerich, Michael Hallek and Hartmut Döhner 2091 Bendamustine Versus Chlorambucil as First-Line Treatment in B Cell Chronic Lymphocytic Leukemia: An Updated Analysis from An International Phase III Study Wolfgang Ulrich Knauf, Toshko Lissitchkov, Ali Aldaoud, Anna Liberati, Javier Loscertales, Roul Herbrecht, Gunnar Juliusson, MD, Gerhard Postner, Liana Gercheva, Stefan Goranov, MD, Martin Becker, Klaus Hoeffken, Francoise Huguet, Robert Foa, MD, Karlheinz Merkle and Marco Montillo 2093 Predicting Time to Initial Treatment in Early Stage CLL - Integration of Classical and Novel Prognostic Factors Michael J. Keating, MB, BS, Susan Lerner, Xuemei Wang, Laura Z. Rassenti, PhD, Susan O'Brien, MD, Thomas J. Kipps, MD, PhD and William G. Wierda, MD, PhD 2094 Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy William G Wierda, MD, PhD, Susan M O'Brien, MD, Xuemei Wang, MS, Stefan H Faderl, MD, Alessandra Ferrajoli, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD, Constantine S Tam, MBBS, Jan A Burger, MD, PhD, Lynne V Abruzzo, MD, PhD, Ellen Schlette, MD, Susan Lerner and Michael J Keating, MBBS Chronic Myelogenous Leukemia 181 High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party Gianantonio Rosti*, Fausto Castagnetti, Angela Poerio, Massimo Breccia, Luciano Levato, Adele Capucci, Mario Tiribelli, Fabio Stagno, Alfonso Zaccaria, Tamara Intermesoli, Bruno Martino, Monica Bocchia, Michele Cedrone, Francesco Bartucci, Francesca Palandri, Gabriele Gugliotta, Nicoletta Testoni, Giuliana Alimena, Giovanni Martinelli, Fabrizio Pane, MD, Giuseppe Saglio and Michele Baccarani 183 Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC) Francois Guilhot, MD, François-Xavier Mahon, MD, PhD, Joelle Guilhot, MSci, Francoise Rigual-Huguet, MD, Frederic Maloisel, MD, Philippe Rousselot, MD, PhD, Martine Gardembas, MD, Selim Corm, MD, Agnes Guerci, MD, PhD, Anne Vekhoff, MD, Gabriel Etienne, MD, Laurence Legros, MD, Jean-Jacques Kiladjian, MD, PhD, Eric Jourdan, Michele Schoenwald, MD, Marc Berger, MD, Virginie Eclache, MD, Catherine Roche-Lestienne, PhD, Franck E Nicolini, MD, PhD and Claude Preudhomme, MD, PhD 186 International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (IM) Stephen G O'Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FRCP, Andreas Hochhaus, MD, Timothy P Hughes, MD, Jerald P. Radich, MD, Marc Rudoltz, MD, Jeiry Filian, Insa Gathmann, MSc, Brian J. Druker, MD and Richard A. Larson, MD 335 A Phase III, Randomized, Open-Label Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (IM) in Patients (pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study Jorge Cortes, MD, Michele Baccarani, MD, François Guilhot, MD, Brian J. Druker, MD, Susan Branford, PhD, Dong-Wook Kim, MD, PhD, Fabrizio Pane, MD, Marc Rudoltz, MD, Richard Yu, LaTonya Collins, RN, BSN, Tillmann Krahnke, PhD, Jerald P. Radich, MD and Timothy P Hughes, MD 1095 Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib Andreas Hochhaus, MD, Martin C Müller, MD, Jerald Radich, MD, Susan Branford, Benjamin Hanfstein, MD, Philippe Rousselot, MD, PhD, Jeffrey H Lipton, MD, PhD, Eric Bleickardt, Ritwik Sinha and Timothy P Hughes, MD 1098 Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib Jorge Cortes, MD, Hagop M Kantarjian, Dong-Wook Kim, MD, PhD, H. Jean Khoury, MD, FACP, Anna G. Turkina, MD, Zhi-Xiang Shen, MD, Tim H Brummendorf, MD, Mammen Chandy, MD, Steven Arkin, MD and Carlo Gambacorti-Passerini, MD 1103 Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABLT315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Franck Nicolini, MD, PhD, Laurence Legros, MD, PhD, Lydia Roy, MD, PhD, Jean-Claude Chomel, MD, Kaddour Chabane, BSc, Sophie Ducastelle, MD, Selim Corm, MD, Mauricette Michallet, MD, PhD, Francois Guilhot, MD, Ali Turhan, MD, PhD and Sandrine Hayette, PhD 2110 Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (PTS) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Gautam Borthakur, Srdan Verstovsek, William Wierda, Jenny Shan and Jorge Cortes, MD 2111 Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian, Gautam Borthakur, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, William G. Wierda, Elizabeth M Burton and Jorge Cortes 2112 Association of Pleural Effusion and Bleeding in Patients with Chronic Myelogenous Leukemia Receiving Dasatinib Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian, Susan O'Brien, MD, Farhad Ravandi, MBBS, Alessandra Ferrajoli, Guillermo Garcia-Manero, MD and Jorge Cortes, MD 2120 Stem Cell Transplant (SCT) for Patients (pts) with Chronic Myeloid Leukemia (CML) Resistant to Tyrosine Kinase Inhibitors (TKI) with BCR-ABL Kinase Domain (KD) Mutation T315I Nikolai Velev, Jorge Cortes, Richard Champlin, Hagop M. Kantarjian, Gabriela Rondon, Sergio Giralt, Gautam Borthakur and Marcos De Lima Myelodysplastic Syndrome 223 Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Per Bernell, Lena-Maria Engström, Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik Jacobsen, Anna Porwit, Peter Hokland and Eva Hellström-Lindberg 224 Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine Hagop Kantarjian, MD, Frank Giles, MD, Peter Greenberg, MD, Ronald Paquette, MD, Eunice Wang, MD, Janice Gabrilove, MD, Guillermo Garcia-Manero, MD, Julie Gray, Kuolung Hu, PhD and Janet Franklin, MD, MPH 226 Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups Pierre Wijermans, Stefan Suciu, Liliana Baila, Uwe Platzbecker, Aristoteles Giagounidis, Dominik Selleslag, Boris Labar, Helmut Salih, Filip Beeldens, Petra Muus, Theo de Witte and Michael Lübbert, MD, PhD 227 The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS) Lewis R. Silverman, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Valeria Santini, MD, Eva Hellström-Lindberg, MD, PhD, Norbert Gattermann, MD, Guillermo Sanz, MD, PhD, Alan F. List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS and C. L. Beach, PharmD 633 Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial Norbert Gattermann, Mathias Schmid, Matteo Della Porta, Kerry Taylor, John F Seymour, Dany Habr, Gabor Domokos, Abdel Hmissi, Agnès Guerci-Bresler and Christian Rose 634 Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS) Alan F List, Maria R Baer, David Steensma, Azra Raza, Jason Esposito, Jodi Virkus, Carole Paley, John Feigert and Emmanuel C Besa 635 Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS) Hagop M Kantarjian, Susan O'Brien, Farhad Ravandi, Jorge Cortes, Jianqin Shan, John M. Bennett, MD, Alan F. List, MD, Pierre Fenaux, MD, PhD and Guillermo Garcia-Manero 1644 The Heterogeneous Prognosis of Patients with Myelodysplastic Syndrome (MDS) and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS? Hagop M Kantarjian, Susan O'Brien, Farhad Ravandi, Gautam Borthakur, Stefan Faderl, Carlos Bueso-Ramos, Lynne Abruzzo, Sherry Pierce, Jianqin Shan, Jean-Pierre Issa and Guillermo Garcia-Manero 1647 Long-Term Cytogenetic Follow-up of MDS Patients with 5q- Treated within the MDS-003 (CC-5013-MDS-003) Study: Evolution to Complex Clones and Progression to AML Gudrun Göhring, MD, Aristoteles Giagounidis, Carlo Aul, Guntram Büsche, MD, Hans Kreipe, MD, Eva Hellström-Lindberg, MD, PhD, Robert D. Knight, MD and Brigitte Schlegelberger, MD 1649 Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome Maria del Mar Mallo, José Cervera, MD, PhD, Julie Schanz, Blanca Espinet, PhD, Esperanza Such, Elisa Luño, MD, PhD, Christian Steidl, MD, María Luisa Martín, Ulrich Germing, Javier Grau, MD, Michael Pfeilstoecker, MD, Jesús M Hernández, MD, PhD, Thomas Noesslinger, M.ª José Calasanz, PhD, Peter Valent, MD, Rosa Collado, MD, PhD, Christa Fonatsch, Encarna Bureo, MD, Michael Lübbert, MD, PhD, Rafael Ríos, MD, PhD, Reinhard Stauder, MD, Eva Arranz, Barbara Hildebrandt, Marilyn L. Slovak, PhD, Juan Cigudosa, PhD, Virginie Eclache, Otto Krieger, Carmen Pedro, MD, Marta Salido, Leonor Arenillas, MD, Guillermo Sanz, MD, PhD, Miguel A. Sanz, MD, PhD, Ana Valencia, Lourdes Florensa, MD, PhD, Detlef Haase, MD, PhD and Francesc SolÃ, PhD 1653 Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA) Valeria Santini, MD, Pierre Fenaux, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Lewis B. Silverman, MD, Alan List, MD, Steven D. Gore, MD, John F Seymour, MBBS, PhD, FRACP, Jay Backstrom, MD, MPH, David McKenzie, MS and C. L Beach, PharmD 2671 Deferasirox Is the Only Iron Chelator Acting as a Potent NF-KB Inhibitor in Myelodysplastic Syndromes Emanuela Messa, MD, Ilaria Defilippi, PhD, Antonella Roetto, PhD, Francesca Messa, PhD, Francesca Arruga, PhD, Sonia Carturan, PhD, Valentina Rosso, PhD, Enrico Bracco, PhD, Daniela Cilloni and Giuseppe Saglio, MD 2688 New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics Julie Schanz, Marilyn L. Slovak, Kazuma Ohyashiki, Francesc Solé, Maria del Mar Mallo, Christian Steidl, Michael Pfeilstoecker, Thomas Noesslinger, Barbara Hildebrandt, Michael Luebbert, Mette K Andersen, Aristoteles Giagounidis, Peter Valent, Christa Fonatsch, Ulrich Germing and Detlef Haase 2689 Characteristics of Disease Progression in 3213 Patients with Myelodysplastic Syndrome Fabian Zohren, Corinna Strupp, Andrea Kuendgen, Aristoteles Giagounidis, Barbara Hildebrandt, Ulrich Suter, Norbert Gattermann, MD, Rainer Haas and Ulrich Germing 3629 Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial John F Seymour, MBBS, PhD, FRACP, Pierre Fenaux, MD, PhD, Lewis B. Silverman, MD3, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Eva Hellström-Lindberg, MD, PhD, Valeria Santini, MD, Alan F. List, MD7, Steven D. Gore, MD, Jay Backstrom, MD, MPH, David McKenzie, MS and C. L. Beach, PharmD Multiple Myeloma 91 Phase II Trial of Lenalidomide (RevlimidTM) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma Shaji Kumar, MD, Suzanne Hayman, Francis Buadi, Martha Lacy, Keith Stewart, Jacob Allred, Kristina Lauman, Tammy McCarty, Leif Bergsagel, David Dingli, Rafael Fonseca, MD, Morie Gertz, Philip Greipp, John Lust, Stephen Russell, Craig Reeder, Thomas Witzig, Steven Zeldenrust, Robert Kyle, S. Vincent Rajkumar and Angela Dispenzieri 649 Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study P. Wijermans, M. Schaafsma, Y. van Norden, R. Ammerlaan, S. Wittebol, H. Sinnige, Sonja Zweegman, M. van Marwijk Kooi, R. Van der Griend, H. Lokhorst and P. Sonneveld 650 Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma Jesus F San Miguel, Rudolf Schlag, Nuriet K Khuageva*, Meletios A Dimopoulos, Ofer Shpilberg, Martin H Kropff, Ivan Spicka, Maria Teresa Petrucci, Antonio Palumbo, Olga S Samoilova, Anna Dmoszynska, Kudrat M Abdulkadyrov, Rik Schots, Bin Jiang, Maria-Victoria Mateos, Kenneth C Anderson, Dixie-Lee Esseltine, Kevin Liu, Andrew Cakana, Helgi van de Velde and Paul Richardson 652 A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients Antonio Palumbo, MD, Sara Bringhen, MD, Davide Rossi, MD, Valeria Magarotto, MD, Francesco Di Raimondo, MD, Roberto Ria, MD, Massimo Offidani, MD, Chiara Nozzoli, MD, Francesca Patriarca, Vincenzo Callea, MD, Giulia Benevolo, MD, Roberto Marasca, MD, Tommasina Guglielmelli, MD, Manuela Rizzo, MD, Mariella Grasso, MD, Maria Teresa Petrucci, MD, Paola Omedè, PhD, Gianluca Gaidano, MD and Mario Boccadoro, MD 653 First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM) P. Sonneveld, B. van der Holt, I. G.H. Schmidt-Wolf, U. Bertsch, L. el Jarari, Hans-Jürgen Salwender, S. Zweegman, E. Vellenga, J. Schubert, I. W. Blau, GSK Jie, B. Beverloo, A. Jauch, D. Hose, R. Schaafsma, M. J. Kersten*, M. Delforge, O. de Weerdt, R. van der Griend, P. W. Wijermans, Hans Martin, H. van der Velde, Henk M. Lokhorst and H. Goldschmidt 656 Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation Gareth J Morgan, MD, PhD, Graham H Jackson, Faith E Davies, MD, Mark T Drayson, Roger G Owen, Walter M Gregory, Dena C Cohen, Alex J. Szubert, Susan E Bell*, Fiona Ross and James A Child 1662 Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities Michele Cavo, MD, Nicoletta Testoni, BS, Carolina Terragna, BS, Giulia Marzocchi, BS, Sandra Durante, BS, Renato Zambello, MD, Chiara Nozzoli, MD, Lucia Pantani, MD, Paola Tacchetti, MD, Luciano Masini, MD, Michela Ceccolini, MD, Paola Agostini, MD, Elena Zamagni, MD, Valerio De Stefano, MD, Patrizia Tosi, MD, Daniele Derudas, MD, Laura Dessanti, MD, Stelvio Ballanti, MD, Salvatore Palmieri, MD, Andrea Nozza, MD, Gioacchino Catania, MD, Jacopo Peccatori, MD, Alfonso D'Arco, MD, Pellegrino Musto, MD, Mariella Grasso, MD, Maria Caterina Pallotti, MD, Silvana Pasini, MD, Pier Paolo Fattori, MD, Anna Baraldi, MD, Delia Cangini, MD, Filippo Ballerini, MD, Alessandro Petrucci, MD and Michele Baccarani, MD 1725 Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors Meletios A. Dimopoulos, Maria Roussou, Efstathios Kastritis, Maria Gavriatopoulou, Flora Zagouri, Magdalini Migkou, Charis Matsouka, Despina Barmparousi, Dimitrios Christoulas, Erasmia Psimenou, Irini Grapsa and Evangelos Terpos 1726 Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or with Bortezomib Depending on Prior Neurotoxicity: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and Assessment of Bone Met Meletios A. Dimopoulos, Efstathios Kastritis, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Flora Zagouri and Evangelos Terpos 1727 Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study Meletios A Dimopoulos, Paul Richardson, Rudolf Schlag, Nuriet K Khuageva, Ofer Shpilberg, Efstathios Kastritis, Martin H Kropff, Maria Teresa Petrucci, Michel Delforge, Julia A Alexeeva, Rik Schots, Tamas Masszi, Maria-Victoria Mateos, William Deraedt, Kevin Liu, Andrew Cakana, Helgi van de Velde and Jesus F San Miguel 1740 Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a Trial Coordinated by the Eastern Cooperative Oncology Group (ECOG) Susanna Jacobus, Shaji Kumar, Natalie Scott Callander, Rafat Abonour, Rafael Fonseca, David Siegel, Philip Greipp and S.Vincent Rajkumar 1742 Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study Paul Richardson, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Sagar Lonial, MD, Noopur Raje, MD, Melissa Alsina, MD, Irene Ghobrial, MD, Amitabha Mazumder, MD, Nikhil C Munshi, MD, David H Vesole, MD, PhD, Kathleen Colson, RN, BSN, BS, Mary L McKenney, Laura Lunde, BA, Sarah Kennedy, BS, Kara Kosakowski, Constantine Mitsiades, MD, PhD, Teru Hideshima, MD, PhD, Robert D Knight, MD, Dixie-Lee Esseltine, MD and Kenneth C Anderson, MD 2767 Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial Darrell J White, MD, Nizar J Bahlis, MD, Deborah C Marcellus, MD, Andrew Belch, MD, A. Keith Stewart, MBChB, MBA, Christine Chen, MD, Michael J Kovacs, MD, David A Macdonald, MD, Donna E Reece, MD, Erica Harnett, MSc, Judy-Anne W Chapman, PhD and Ralph M Meyer, MD Non-Hodgkin Lymphoma 3 Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL) Jonathan W. Friedberg, MD, Jeff Sharman, Julia Schaefer-Cutillo, Patrick B. Johnston, Sven De Vos, MD, PhD, Ann LaCasce, MD, John P. Leonard, MD, Larry D. Cripe, MD, Rajni Sinha, MD, Stephanie A. Gregory, John Sweetenham, Julie M. Vose, MD, Ann M Lowe, MD, R. Levy and Margaret A. Shipp, MD 1559 Supportive Efficacy Analyses for the Phase 3 Study of Temsirolimus Versus Investigator's Choice Therapy for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma Jorge Romaguera, Bertrand Coiffier, Michael Crump, Raoul Herbrecht, Gregor Verhoef, Orysia Hanushevsky, Andrew Strahs, Becker Hewes, Anna Berkenblit and Georg Hess 1560 The Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Bortezomib: Pooled Data from Two Phase II Studies (NHL-002 and NHL-003) Craig B. Reeder, MD, T.E. Witzig, Julie M. Vose, Pier Luigi Zinzani, MD, Rena Buckstein, MD, FRCPC, Corinne Haioun, Reda Bouabdallah, MD, Jonathan Polikoff, MD, Pingshan Guo, Annette Ervin-Haynes, Dennis Pietronigro, Jerome B. Zeldis, MD and Myron S. Czuczman, MD 1561 Farnesyltransferase Inhibitor Tipifarnib (Zarnestra) in Refractory Mantle Cell Lymphoma (MCL): A Therapeutic Target Only for Specific Patients Categorized by the 2-Gene Classifier for Predictive Response to Tipifarnib Delphine Rolland, Vincent Ribrag, Corinne Haioun, Herve Ghesquieres, MD, Fabrice Jardin, Reda Bouabdallah, Patricia Franchi, Josette Briere, Eric De Kerviler, Catherine Chassagne-Clement, Mitch Raponi, PhD, Remi Houlgatte, Jean-Philippe Jais and Catherine Thieblemont 1572 Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma Nicholas Di Bella, MD, Raymond Taetle, MD, Kathryn S. Kolibaba, MD, Thomas E Boyd, MD, Robert N Raju, MD, David N Barrera, DO, Ernest Cochran, MD, Philip Dien, MD, David Hakimian, MD, Roger M. Lyons, MD, Peter J Schlegel, MD, Svetislava J Vukelja, MD, Julie Boston, RN, Kristi A Boehm, MS, Yunfei Wang, MS and Lina Asmar, PhD 1763 Absolute Lymphocyte Count at the Time of Relapse Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Luis F. Porrata, MD, Kay Ristow, Thomas M Haberman, MD, Thomas E Witzig, MD, David James Inwards, MD, Stephen M Ansell, MD, PhD, Patrick B Johnston, MD, PhD, Ivana N. Micallef, MD, Joseph P Colgan, MD, William L White, MD and Svetomir N Markovic, MD, PhD 2589 Characteristics of Refractory and Relapsing Patients with Diffuse Large B-Cell Lymphoma Bertrand Coiffier, Gilles Salles, MD, PhD, Andre Bosly, MD, PhD, Philippe Gaulard, MD, Corinne Haioun, Olivier Casasnovas, MD, Nicolas Mounier, MD, Marie Helene Delfau, MD, Catherine Sebban, MD, Pierre Feugier, MD, Christian Recher, MD, PhD, Richard Delarue, Nicolas Ketterer, Herve Tilly, MD and Christian Gisselbrecht 2596 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Studygroup Indolent Lymphomas (StiL) Mathias J Rummel, Ulrich von Gruenhagen, Norbert Niederle, Harald Ballo, Eckhart Weidmann, Manfred Welslau, Gerhard Heil, Christina Balser, Heinz A Duerk, Martina Stauch, Dorothea Kofahl-Krause, Ulrich Kaiser, Wolfgang Knauf and Wolfram Brugger, MD 2599 Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months Christian Buske, Dr, Eva Hoster, Martin Dreyling, Roswitha Forstpointner, Michael Kneba, MD, PhD, Norbert Schmitz, Rudolf Schmits, Bernd Metzner, Marcel Reiser, Eva Lengfelder Bernhard J Woermann, Harriet Harder, Susanna Hegewisch-Becker, Wolfgang E. Berdel, Georg Hess, Hartmut Eimermacher, Ali Aldaoud, Manfred Planker, Michael Unterhalt and Wolfgang Hiddemann, MD 2603 Late Relapse of Localized High-Grade Non-Hodgkin's Lymphoma: Clinical and Biological Features Gandhi Damaj, MD, Marc Bernard, MD, Steven Legouill, MD, Guillaume Cartron, MD, PhD, Annie Le Mevel, MD, Céline Dubus, Christian Berthou, Md, PhD, Philippe Colombat, MD, PhD, Noel Milpied, MD, PhD, Jean Pierre Marolleau, MD, PhD and Thierry Lamy, MD, PhD 2832 FLIPI and F2 Index – Prognostic Indices in Advanced Stage Follicular Lymphoma Michael Unterhalt, PhD, Eva Hoster, Martin Dreyling, Christian Buske and Wolfgang Hiddemann, MD 3588 The Baseline PET SUV Correlates Better with Clinical Outcome Than the Post-Therapy PET Scan in Previously Untreated Patients with Histologically Aggressive Non-Hodgkin Lymphoma (NHL) Fernando Cabanillas, MD, Jorge Toro, Jorge Perdomo, Orestes Pavia, Idalia Liboy, Clara Salgado, Viviana Freire, Ezequiel Rivera and Norman Maldonado

Source: http://www.educationalconcepts.net/arc/oncobeat/pdf/ash_references.pdf